The increase of hematopoiesis turbulence by the last years of life is typical for patients with metastatic
non-small cell lung cancer (NSCC) that leads to the risk of their overtreatment. The hematopoietic
stem cells (HSC) and mitotic index (MI) in the blood’ lymphocytes of thirty-five patients were
measured by flow cytometry before conventional cytotoxic therapy and then compared with their life
span after treatment. The plot of the individual product (CD133+HSC × MI) versus CD34+HSC
revealed the prognostic properties during the survival period (range 0.3–124 months). Discrimination
of patients with an expected survival shorter than 12 months was possible based on the positions of
individual points on the plot, with a sensitivity and specificity of ~100 each and a diagnostic odds ratio
of 1250. The ratio of lymphoproliferative potency and the cumulative dose of systemic hematosuppressive
therapy determines the prevalence of cancer growth suppression or an adverse effect on the physiological
systems responsible for maintaining the viability of the host organism. The higher potency associates with a
longer duration during which the therapy may be successful, and vice versa.The proposed competitive mechanism
for tumor control in the host assumes the partial distraction the trophic circulating cells from tumor to offside
tissue priorities, like reparation of a multitude of hematopoietic and other non-malignant cells injured sub-lethally.
The stronger the trophic influence of lymphopoiesis on the tissues of the cancer host is, the higher the probability
and benefit of this therapeutic mechanism will be. The definition an activation of anticancer immunity is better to
replace on definition a reduction of tumor morphogenesis.The main task for future investigations is the
phases of cyclic lymphopoiesis, which are optimal for the induction of regenerative processes outside
the tumor in surrounding tissues.
Author (s) Details
Aleksey N. Shoutko
Laboratory for Improvement of the Radiation Treatment Methods, Federal Research Center for Radiology and Surgical Technologies, Saint-Petersburg, Russia.
Victor F. Mus
Group for Lung Cancer Treatment, Federal Research Center for Radiology and Surgical Technologies, Saint-Petersburg, Russia.
Dmitry N. Maystrenko
Department of Vascular Surgery, Federal Research Center for Radiology and Surgical Technologies, Saint-Petersburg, Russia.
View Book :- https://bp.bookpi.org/index.php/bpi/catalog/book/270